|
|
Date de rédaction : 24 décembre 2010 |
Bibliographie
Bilan d'extension et prise en charge
Stahl
M, Kataja VV, Oliveira J; ESMO Guidelines Task Force.
ESMO Minimal Clinical Recommendations for diagnosis, treatment
and follow-up of esophageal cancer.
Ann Oncol 2005;16 Suppl 1:i26-7.
Lightdale
CJ, Kulkarni KG.
Role of endoscopic ultrasonography in the staging and follow-up
of esophageal cancer.
J Clin Oncol 2005;23:4483-9.
Place de la chirurgie
Hofstetter
W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA et al. Treatment outcomes of resected esophageal cancer.
Ann Surg 2002;236:376-84
Akiyama
H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node
dissection for cancer of the thoracic esophagus.
Ann Surg 1994 ;220 :364-72
Hulscher
JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG,
Fockens P et al. Extended transthoracic resection compared
with limited transhiatal resection for adenocarcinoma of the
esophagus.
N Engl J Med 2002;347:1662-9

Place de la chimiothérapie préopératoire
Medical
Research Council œsophageal Cancer Working Group.
Surgical
resection with or without preoperative chemotherapy in œsophageal
cancer : a randomised controlled trial.
Lancet 2002 ;359:1727-33
Allum WH, Stenning SP, Bancewicz J et al.
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
J Clin Oncol. 2009;27: 5062-7.
V. Boige, J. Pignon, B. Saint-Aubert, P. Lasser, T. Conroy, O. Bouché, et al.
Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone
in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial.
J Clin Oncol, 2007 ; 25, 18S (Suppl. Part I): résumé 4510
P. G. Thirion, S. Michiels, A. Le Maître, J. Tierney, on behalf of the MetaAnalysis of
Chemotherapy in Esophagus Cancer Collaborative Group.
Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable
œsophageal carcinoma.
J Clin Oncol, 2007 ; 25, 18S (Suppl. Part I): résumé 4512

Place de la radiochimiothérapie
préopératoire
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J.
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in œsophageal carcinoma: a meta-analysis.
Lancet Oncol 2007;8:226-34.
Place et modalités de la chimioradiothérapie
Minsky
BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki
R, et al.
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III
trial of combined-modality therapy for esophageal cancer:
high-dose versus standard-dose radiation therapy.
J Clin Oncol 2002;20:1167-74.
Wong
RK, Malthaner RA, Zuraw L, Rumble RB
Combined modality radiotherapy and chemotherapy in nonsurgical
management of localized carcinoma of the esophagus: a practice
guideline.
Int J Radiat Oncol Biol Phys 2003;55:930-42.
Thomas
CR, Berkey BA, Minsky BD, Gaspar LE, Herskovic A, Rich
TA, et al.
Recursive partitioning analysis of pretreatment variables
of 416 patients with locoregional esophageal cancer treated
with definitive concomitant chemoradiotherapy on Intergroup
and Radiation Therapy Oncology Group trials.
Int J Radiat Oncol Biol Phys2004;58:1405-10.
|